Trial Watch: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Important context
- Trial eligibility (participation has strict criteria): Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
In plain English
The 30-second version
What happened?
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
Why does it matter?
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
What does this not prove?
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Keep reading for evidence stage, limitations, study details, and sources.
What changed: ClinicalTrials.gov lists Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (NCT02112916) as a Phase 3 interventional cancer study. The registry status is Active Not Recruiting, with the record last updated 2026-10-21.
Study snapshot: Phase 3; Active Not Recruiting; planned enrollment 847. Conditions listed: Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma. A primary outcome listed by the registry is: Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients.
This entry tracks verified trial-registry facts. Trial registration by itself does not show that an intervention is effective, safe for a particular person, FDA-approved for this use, or recommended by clinical guidelines.
Population / Applicability
Studied in: Participants ages 1 Year to 30 Years with Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma who meet the study-specific registry eligibility criteria. (Mixed / all ages)
Eligibility is study-specific. Registry information does not determine whether any individual should enroll in or receive the intervention.
Full evidence details
- Study design
- Other / not applicable
- Sample size
- 847
- Primary outcome
- Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
- Replication
- Unknown
Funding & Conflicts
ClinicalTrials.gov lists the lead sponsor as National Cancer Institute (NCI). Sponsorship is reported for transparency and does not establish efficacy.
Regulatory status by jurisdiction
Unspecified jurisdiction
- Status
- Investigational
- Last verified
- 2026-10-22
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Guideline positions
Guideline
- Position
- Not addressed
- Last verified
- 2026-10-22
Primary evidence supporting this story
- ClinicalTrials.gov — NCT02112916 (opens in a new tab) (Clinical-trial registry) NCT02112916 Load-bearing source NCT02112916
ClinicalTrials.gov — NCT02112916. NCT02112916.
Last reviewed
Trial Watch: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
https://cancerdiscoveries.com/discoveries/trial-watch-combination-chemotherapy-with-or-without-bortezomib-in-treating-younger-patients-with-newly-diagnosed-t-cell-acute-lymphoblastic-leukemia-or-stage-ii-iv-t-cell-lymphoblastic-lymphoma/
Evidence stage: Later-Stage Human
What This Means
ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
What This Doesn't Mean
A registered trial is not proof that the intervention works, is not FDA approval for this cancer or use, and is not a clinical-guideline recommendation.
Why It Matters
Phase 3 trials can contribute later-stage human evidence. CancerDiscoveries can track this record as results and regulatory information emerge.
Important Limitations
- Clinical-trial participation has study-specific eligibility criteria; registry listing does not mean a person qualifies or should enroll.
Primary sources
- ClinicalTrials.gov — NCT02112916 — https://clinicaltrials.gov/study/NCT02112916 (NCT02112916)
Date verified: 2026-10-22
Correction status: No correction or retraction